Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARVEL-MPSS: Methylprednisolone in Acute Disabling Non-LVO Ischemic Stroke
ChiCTR2600121588Phase 3Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylprednisolone sodium succinate in ischemic stroke (2 arms), sponsored by Xinqiao Hospital. Primary endpoints: Proportion of patients with 90-day mRS score 0–1, Symptomatic intracranial hemorrhage within 48 hours and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
methylprednisolone sodium succinate
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600121588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121588.